Saturday, 4th February 2023
<To guardian.ng
Search
Breaking News:

NHIA, Pfizer sign drug cost-sharing pact for treatment of infections

By Nkechi Onyedika-Ugoeze, Abuja
18 October 2022   |   4:02 am
National Health Insurance Authority (NHIA) has signed a Memorandum of Understanding (MOU) on cost sharing with a leading biotech company, Pfizer, on dispensing of critical antibiotics medicine Meronem(c) (MEROPENEM) for treatment of infections.

National Health Insurance Scheme (NHIS), Prof. Mohammed Nasir Sambo

National Health Insurance Authority (NHIA) has signed a Memorandum of Understanding (MOU) on cost sharing with a leading biotech company, Pfizer, on dispensing of critical antibiotics medicine Meronem(c) (MEROPENEM) for treatment of infections.

Under the arrangement, Pfizer is bearing 50 per cent of the cost of the drug while NHIA would foot 30 per cent and the enrollees bear the rest 20 per cent.

Speaking at the ceremony, yesterday, in Abuja, NHIA Director General, Prof. Mohammed Sambo, explained that the agency was partnering with pharmaceutical companies to make drugs available, affordable, accessible and acceptable to enrollees at a reduced cost.

He observed that medicine supply remained a major component of assessing healthcare, as much as enrollees must visit hospitals and get prescriptions due to the out-of-stock syndrome at the medical facilities.

Represented by the General Manager Finance and Account, John Gboko, the NHIS boss said the signing was a milestone geared at improving the health statuses of Nigerians.

He added that an implementation committee would be raised to draw up a roadmap.

Also speaking, Pfizer West Africa Country Manager, Olayinka Subair, while noting that the best approach to manage healthcare is through health insurance, hinted that the firm was coming up with critical care products for managing infections.

He stated that antimicrobial resistance is responsible for about two million deaths yearly, with most of the fatalities occurring in developing countries faced with inadequate drugs.

According to him, the innovative medicine would tackle the problem his organisation and NHIA had partnered over.